Results 191 to 200 of about 83,505 (263)

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang   +10 more
wiley   +1 more source

Primary Gastric Hodgkin Lymphoma: A Case Report. [PDF]

open access: yesMiddle East J Dig Dis
Ben Hammamia H   +7 more
europepmc   +1 more source

Environmental Pesticide Exposure in the Etiology of Pediatric Brain Tumors and Leukemia: A Scoping Review of Epidemiological Studies

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1360-1384, 15 September 2026.
ABSTRACT Pediatric cancer is a significant cause of morbidity and mortality in children. The etiologies of pediatric cancer are largely unknown, but environmental pesticide exposures are likely to contribute. Chronic low‐dose exposure to pesticide mixtures through drinking water is a growing concern in agricultural communities.
Grace N. VanDeSteeg   +4 more
wiley   +1 more source

Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2123-2136, September 2026.
ABSTRACT Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer‐associated clinically relevant bleeding (CRB) in ...
Ming Y. Lim   +11 more
wiley   +1 more source

Focus on Extremely Late Relapses in Hodgkin Lymphoma: A Single Center Analysis. [PDF]

open access: yesCancers (Basel)
Liaskas A   +5 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

The impact of tuberculosis misdiagnosis in Hodgkin lymphoma patients. [PDF]

open access: yesIndian J Med Res
Singh C   +7 more
europepmc   +1 more source

The IL‐10/IL‐6 Ratio and the Risk Score: Two Cytokines‐Based Predictors for Malignancy‐Associated Hemophagocytic Lymphohistiocytosis in Adults (M‐HLHa)

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2214-2224, September 2026.
ABSTRACT The predictive value of cytokines (CK) for malignancy‐associated adult hemophagocytic lymphohistiocytosis (M‐HLHa) remains uncertain. We evaluated a cytokine‐based Risk Score (RS) and the IL‐10/IL‐6 Ratio to predict M‐HLHa. Adult patients (n = 112) from the French HLH cohort (NCT02113917) with complete data for nine key HLH related CK measured
Coralie Bloch   +47 more
wiley   +1 more source

Home - About - Disclaimer - Privacy